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ABSTRACT
Objective: To compare the efficacy and adverse drug reactions of monotherapy and combination therapy of antihypertensive drugs in diabetic 
hypertensive patients.
Methods: A prospective observational study of 18 months duration was conducted in the Department of Medicine of a tertiary care hospital in 
South India. A total of 200 patients were included in the study. Using a standard proforma, the details of patients such as demographic data and 
antihypertensive medications were collected and analyzed for efficacy and safety.
Results: Of 200 patients studied, 50% received monotherapy whereas the remaining 50% received combination therapy. There was male 
preponderance (54%) in the study population, with the mean age being 60.07±11.32 years. In monotherapy group, most commonly prescribed drug 
was amlodipine (38%), whereas in combination group, angiotensin receptor blocker (ARB) or calcium channel blocker (CCB) + beta blocker (18%) 
was commonly prescribed among 2-drug group and ARB+ thiazide+ CCB (25.6%) among 3-drug group. Monotherapy and combination therapy were 
analyzed to be equally efficacious in reducing systolic blood pressure and diastolic blood pressure. Based on the adverse effect profile, monotherapy 
comparatively produced more adverse effects than combination group. Amlodipine-induced pedal edema (56.7%) was the most common adverse 
effect observed, and it was predominantly managed by changing it to be a better tolerable CCB, namely cilnidipine.
Conclusion: The combination therapy may be a better treatment option in selected patient population.
Keywords: Systolic blood pressure, Diastolic blood pressure, Amlodipine, Cilnidipine, Pedal edema.
INTRODUCTION
Hypertension (HTN) is one of the most common chronic diseases 
and is defined as systolic blood pressure (SBP) ≥140mm Hg and/or 
diastolic blood pressure (DBP) ≥90mm Hg [1]. It exerts a considerable 
health burden on the public regarding its significance in cardiovascular 
health and thereby the well-being in India [2,3]. HTN is unswervingly 
accountable for 57% of all stroke and 24% of all coronary heart disease 
(CHD) deaths in India [4] and this correlation is more associated with 
SBP than with DBP [5]. Globally, it is indeed a vital test in public health 
due to its high occurrence and related death [6-8].
HTN is a very familiar comorbid state in diabetes wherein 
approximately 20-60% of patients with diabetes are affected. 
HTN extensively intensifies the danger of both macrovascular and 
microvascular complications, including cerebrovascular disease, 
CHD, and peripheral vascular disease. Based on convincing data, 
pharmacological therapy of HTN in patients with diabetes is effective 
in producing considerable decrease in these complications. The 
presence of a firm epidemiological relation between HTN in diabetes 
and undesirable consequences of diabetes has been established, 
but reduced information from trials evaluating different classes of 
antihypertensive drugs in patients with HTN associated with diabetes 
still persists [9]. The intricacy of various pathophysiological processes 
that lead to rise in BP is such that a judicious and systematic mode of 
antihypertensive treatment is hardly achievable in any hypertensive 
patient [10]. However, there are a variety of drugs available for the 
treatment which can be used alone or in combination to reduce 
arterial pressure accordingly [11].
The present-day recommendations include a universal approach in 
controlling HTN, with not much importance given on determining a 
curative modality based on the various underlying pathophysiology of 
HTN. Considering the fact that there has been an improved understanding 
of a specific etiology, it has now become feasible to develop therapies 
selective for distinct pathophysiological mechanisms with fewer adverse 
effects, resulting in more effective BP reduction [12,13]. Thus, it is 
considered that with the practice of novel usage of hereditary science 
unified with an understanding of systemic functioning and population 
studies, there will be more selective and efficacious methods possible in 
treating and even averting HTN in the future years [14,15].
Hence, considering the fact that there have been limited data from 
trials comparing monotherapy and combination therapy of different 
classes of antihypertensive drugs in patients with diabetes and HTN, 
the present study was planned to assess the efficacy and adverse effects 
of monotherapy and combination therapy of antihypertensive drugs 
among diabetic hypertensive patients.
METHODS
This prospective observational study was conducted in the Department 
of Medicine of a tertiary care hospital in South India for 18 months 
(1st November 2013 to 30th April 2015). The Institutional Ethics 
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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Committee (IEC) clearance was obtained before initiation of the study 
(letter no. IEC 513/2013). A total of 200 diabetic hypertensive patients 
fitting into the subject selection criteria were included in the study. 
They were broadly divided into two treatment groups that included 
monotherapy and combination therapy groups wherein combination 
was further divided into 2-drug and 3-drug combination groups; hence, 
Group 1 is monotherapy, Group 2 is 2-drug, and Group 3 is 3-drug 
combination group. Subject selection criteria were as follows:
Inclusion criteria
1. Patient of either male or female sex and age group of 18-80 years 
diagnosed with diabetic HTN.
2. Diabetic hypertensive patients with comorbidities such as stroke 
and myocardial infarction.
Exclusion criteria
1. Patients diagnosed to have chronic kidney diseases (having creatinine 
values >2 mg/dL), peripheral vascular diseases, and respiratory 
comorbidities.
2. Patients on steroid medications.
3. Pregnant and lactating mothers.
Patients (outpatients) fulfilling the study criteria were included after 
obtaining consent and were reviewed for efficacy and adverse drug 
reaction (ADR) of the prescribed drugs.
1. Demographic and clinical data of each patient (age, sex, and available 
laboratory reports) were collected.
2. Efficacy of monotherapy and combination therapy of antihypertensive 
drugs was compared.
• Baseline value was obtained based on patient’s initial visit before 
treatment.
• Two follow-up BP values were noted following the initiation of 
treatment (ideally, at 4th and 8th week after starting treatment).
• The percentage decrease in SBP and DBP observed over a period 





Baseline BP  Second follow up 
visit reading at end of study
Percentage reduction in BP 100
Baseline
3. The details of suspected ADRs were documented in a suitably 
designed Central Drugs Standard Control Organization suspected 
ADR form. Causality assessment was done using the World Health 
Organization-Uppsala Monitoring Centre (WHO-UMC) causality 
assessment system [16].
Statistical analysis
Demographic data were analyzed using descriptive statistics. For efficacy 
parameter, the mean percentage reduction in BP from baseline to the end 
of the study (at 2nd follow-up visit) was calculated for individual drugs 
and combinations in all the three groups. Mean SBP and DBP before and 
after treatment within each group was compared using paired t-test. 
Mixed design analysis of variance (ANOVA) model was used to compare 
SBP and DBP between the groups. p<0.05% was considered statistically 
significant. ADRs were analyzed using descriptive approach. Data were 
analyzed using SPSS software version 16.
RESULTS
A total of 200 outpatients having HTN associated with diabetes, based 
on the subject selection criteria, were enrolled and analyzed for 
demographic characteristics, drug utilization pattern, efficacy analysis 
of treatment group, and ADR due to prescribed drugs.
Patients were divided eventually into three groups depending on the 
treatment they received as shown in Table 1. The mean age of patients 
in the study population was 60.07±11.32 years. They were divided into 
different age groups (Fig. 1). The majority of the patients were in the 
60-69 years age group (32%) followed by 50-59 years age group (28%). 
There was a male predominance (54%) in the study population (Fig. 2).
As shown in Table 2, among all the 100 patients receiving 
monotherapy, most of the patients received amlodipine (38%) 
followed by enalapril (23%). The least prescribed drug among 
patients receiving monotherapy was clonidine (4%). In Group 2 
containing 61 patients, the most commonly prescribed combinations 
were beta blocker + calcium channel blocker (CCB) and angiotensin 
receptor blocker (ARB) + CCB (18%) as shown in Table 3. Moreover, 
among Group 3 that comprised 39 patients, the most commonly 
prescribed combination group was ARB + thiazide + CCB (25.6%) as 
shown in Table 4.
The percentage reduction in SBP among monotherapy group is shown 
in Table 5. The highest reduction was seen in metoprolol group (16.8%) 
Table 1: Group-wise distribution of patients
Drug group Number of patients (n=200)
Group 1 (monotherapy) 100
Group 2 (2 drug combination) 61
Group 3 (3 drug combination) 39
Table 2: Drug utilization pattern in monotherapy group








ACE: Angiotensin-converting enzyme, CCB: Calcium channel blocker, 
ARB: Angiotensin receptor blocker
Fig. 1: Age group distribution of patients
Fig. 2: Gender distribution of patients in percentage
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followed by enalapril group and the least reduction was seen in the 
telmisartan group (12.6%). All the medications in Group 1 brought 
about a statistically significant reduction in percentage decrease in 
SBP. As shown in Table 6, patients treated with cilnidipine showed the 
highest reduction in DBP (15.1%) followed by amlodipine (12.8%). 
Least reduction in DBP was seen in prazosin group (11.1%) which was 
not statistically significant. All the other drugs in the monotherapy 
group showed a statistically significant decrease in DBP. In Group 2, 
angiotensin-converting enzyme (ACE) inhibitor + CCB combination 
showed the greatest reduction in SBP (15.6%) followed by alpha 
agonist + CCB combination (15.3%). Least reduction in SBP was seen 
in thiazide + CCB combination (11.8%). The percentage reduction in 
SBP was statistically significant in all the combinations in Group 2 as 
shown in Table 7. ARB or beta blocker + CCB combination showed 
the maximum percentage reduction in DBP (12.5%) followed by ACE 
inhibitor + CCB combination (11.9%). The least reduction was observed 
in thiazide + CCB group. The reduction was statistically significant with 
all the drug combinations as shown in Table 8. As shown in Table 9, in 
Group 3, there was a comparatively higher percentage reduction in SBP 
seen in the ARB + CCB + alpha agonist group (17.1%), the least being 
in the ACE inhibitor + CCB + alpha agonist group (9.6%). All the results 
were statistically significant. As shown in Table 10, ARB + thiazide + 
CCB (14.4%) combination showed greater percentage decrease in DBP 
with the least decrease seen in ACE inhibitor + CCB + alpha agonist 
(11.6%) combination. The reduction was statistically significant with 
all the combinations. The fall in SBP and DBP, when compared to the 
three groups, at baseline and 1 and 2 months, was not statistically 
significant as per the analysis done using mixed design ANOVA 
(Figs. 3 and 4).
As shown in Tables 11-14, of 200 patients, 30 (15%) patients developed 
ADRs. Most of the drug reactions were seen in the monotherapy group 
(66.7% of the total ADRs). Rest of the ADRs were seen among the 
combination groups (33.3% of total ADRs). Amlodipine-induced pedal 
edema was the most common ADR among the three groups (56.7%). 
All ADRs were classified as “possible” according to WHO-UMC causality 
assessment scale.
DISCUSSION
The present study suggested that most of the patients (32%) having 
HTN associated with diabetes belong to age group of 60-69 years 
followed by 28% belonging to the age group of 50-59 years; the 
mean age of the study population was 60.07±11.32 years. The least 
percentage of patients (0.5%) was seen in 20-29 years age group. 
Supporting this, according to Everett et al., the incidence of HTN was 
more commonly seen in patients below 65 years (85.9-87.7%) in 
comparison to patients above 65 years (12.3-14.0%) [17]. Lacourciere 
et al. [18] and Ruilope et al. levels [19] had also been consistent with 
the current study showing the mean age to be 60-61 years; however; in 
a study carried out by Yasmeen et al., 31.7% patients belonged to 51-
60 years age group followed by 28.9% in 41-50 years age group with 
the least (3.5%) being 71-80 years age group [20]. The rationale for an 
increase in blood pressure with age could probably be due to structural 
changes in the arteries and especially with large artery stiffness [21].
In the present study, there was male preponderance in patients 
having HTN with diabetes (54%). Previous studies conducted in India 
(Yasmeen et al., Jaganan et al.), USA (Everett et al.), Nepal (Pandaya 
et al.), and Australia (White et al.) have also reported that the incidence 
of HTN with diabetes mellitus was higher in males compared to 
females [17,20,22-24]. This could probably be due to significantly 
higher awareness, treatment, and control rates among women than 
men as supported by a recent data from the 2007 to 2010 National 
Health and Nutrition Examination Survey [25].
The most common groups of antihypertensive drugs such as CCBs, 
beta blockers, ACE inhibitors, ARBs, alpha blockers, alpha agonists, 
and diuretics were used to treat HTN in the present study. Among 
these, the most frequently used antihypertensive as monotherapy 
was amlodipine (38%) followed by enalapril (23%). Alavudeen et al. 
showed similar finding wherein the most commonly prescribed drug 
among monotherapy was CCB (34.3%) followed by ACE inhibitors 
(29.9%) [26]. This was also seen by Kousalya et al., where amlodipine 
(83.8%) was the most commonly used drug [27]. Diuretics were not 
prescribed as a monotherapy in this study, which was different from 
studies done by Tamuno and Fadare and Etuk et al. wherein diuretics 
were the regularly prescribed drug (41.2% and 44.8%, respectively) 
as monotherapy [28,29]. However, according to the WHO guidelines, 
ACE inhibitors are ideally regarded as the favored therapy in patients 
with HTN and diabetes [30]. Findings from the heart outcomes 
prevention evaluation study also support the above guidelines [31]. 
According to Bronsert et al., Kaur et al., Jaganan et al., and Beulah 
et al., the most commonly prescribed class of drug was ACE 
inhibitor (43.6%, 33.8%, 52.3%, and 56.7%, respectively) [22,32-34].
Table 3: Drug utilization pattern in 2-drug combination group
Drugs Number of patients (%)
ACE inhibitor+CCB 10 (16.4)
Alpha agonist+CCB 10 (16.4)




CCB: Calcium channel blocker, ARB: Angiotensin receptor blocker, *Others 
represent ARB+alpha2 agonist, ACE inhibitors+Alpha2 agonist, loop 
diuretics+CCB etc., ACE: Angiotensin-converting enzyme
Table 4: Drug utilization pattern in 3 drug combination group
Drugs Number of patients(%)
ARB+thiazide+CCB 10 (25.6)
ACE inhibitor+CCB+alpha agonist 09 (23.1)
ARB+CCB+alpha agonist 09 (23.1)
Others* 11 (28.2)
CCB: Calcium channel blocker, ARB: Angiotensin receptor blocker, *Others 
represent β-blocker+alpha blocker+alpha2 agonist, beta blocker+thiazide+alpha 
blocker etc., ACE: Angiotensin-converting enzyme
Table 5: Effect of monotherapy on systolic blood pressure (n=100)





Baseline (mean±SD) After (mean±SD)
Amlodipine 162.6±11.0 137.2±13.3 25.4±4.2 15.6 <0.001*
Enalapril 158.7±6.9 132.4±7.3 26.3±7.9 16.6 <0.001*
Cilnidipine 159.6±7.4 133.7±8.8 25.8±5.6 16.2 <0.001*
Metoprolol 160.0±8.6 133.1±12.9 26.8±11.9 16.8 <0.001*
Prazosin 160.0±7.0 138.0±8.3 22.0±4.4 13.7 <0.001*
Telmisartan 162.0±8.3 141.6±2.1 20.4±6.5 12.6 <0.05*
Clonidine 155.0±5.7 132.5±12.5 22.5±9.5 14.5 <0.05*
SD: Standard deviation, SBP: Systolic blood pressure, mm Hg is Millimeter of mercury, SD is standard deviation for n=100 observations. *represents statistical 
significance
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Table 6: Effect of monotherapy on diastolic blood pressure (n=100)





Baseline (mean±SD) After (mean±SD)
Amlodipine 95.4±9.3 83.2±7.1 12.2±6.2 12.8 <0.001*
Enalapril 95.0±5.8 83.4±6.4 11.5±6.0 12.2 <0.001*
Cilnidipine 92.0±6.5 78.1±6.5 13.8±6.3 15.1 <0.001*
Metoprolol 91.1±7.8 80.0±5.0 11.1±6.0 12.2 <0.05*
Prazosin 90.0±7.0 80.0±7.0 10.0±10.0 11.1 0.089
Telmisartan 96.0±5.4 84.0±5.4 12.0±4.4 12.5 <0.05*
Clonidine 95.0±5.7 84.0±4.8 11.0±2.0 11.6 <0.05*
SD: Standard deviation, DBP: Diastolic blood pressure, mm Hg is Millimeter of mercury, SD is standard deviation for n=100 observations. *represents statistical 
significance
Table 7: Effect of 2 drug combination on systolic blood pressure (n=61)





Baseline (mean±SD) After (mean±SD)
ACE inhibitor+CCB 162.4±4.1 137.0±11.5 25.4±9.5 15.6 <0.001*
Alpha agonist+CCB 184.6±13.5 156.2±11.6 28.4±6.9 15.3 <0.001*
Beta blocker+CCB 159.8±6.0 137.0±8.2 22.7±8.0 14.2 <0.001*
ARB+CCB 165.5±12.1 140.3±11.8 25.0±9.6 15.2 <0.001*
Thiazide+CCB 155.0±5.3 136.7±6.4 18.2±8.2 11.8 <0.001*
Others 160.0±7.7 134.0±10.1 26.0±10.7 16.2 <0.001*
SD: Standard deviation, SBP: Systolic blood pressure, CCB: Calcium channel blocker, ARB: Angiotensin receptor blocker, mm Hg is Millimeter of mercury, SD is standard 
deviation for n=61 observations, *represents statistical significance, ACE: Angiotensin-converting enzyme
Table 8: Effect of 2-drug combination on diastolic blood pressure (n=61)





Baseline (mean±SD) After (mean±SD)
ACE inhibitor+CCB 92.0±9.1 81.0±7.3 11.0±5.6 11.9 <0.001*
Alpha agonist+CCB 98.4±6.0 88.0±4.2 10.4±3.6 10.5 <0.001*
Beta blocker+CCB 94.5±5.2 82.7±6.4 11.8±6.0 12.5 <0.001*
ARB+CCB 96.7±8.8 84.5±6.8 12.1±6.6 12.5 <0.001*
Thiazide+CCB 91.2±3.5 83.0±4.5 8.2±3.6 9.0 <0.001*
Others 91.8±6.0 79.0±7.0 12.7±7.8 13.8 <0.001*
SD: Standard deviation, CCB: Calcium channel blocker, ARB: Angiotensin receptor blocker, mm Hg is Millimeter of mercury, SD is standard deviation for n=100 
observations, *represents statistical significance, ACE: Angiotensin-converting enzyme
Fig. 3: Comparison of fall in systolic blood pressure between 
monotherapy and combination group
Fig. 4: Comparison of fall in diastolic blood pressure between 
monotherapy and combination group
It was seen in the current study that majority of the patients received 
beta blocker + CCB (18%) and ARB + CCB (18%) among the 2-drug 
combination group. This is in agreement with the study conducted by 
Panda et al., wherein the most common 2-drug combination prescribed 
was CCB+ beta blocker (30.3%) followed by CCB + ARB (25.9%) [35]. 
Alavudeen et al. also reported that CCB+ARB (25%) was the common 
drug prescribed among the 2-drug combination group [26]. However, 
most of the other studies had shown an inconsistent finding with the 
present study in relation to the most common 2-drug combination 
drugs prescribed. Tamuno and Fadare and Pandaya et al. reported 
that the most commonly used 2-drug combination was CCB + diuretic 
(12% and 37.8%, respectively) [23,28]. According to Kausalya et al., 
ACE inhibitor + CCB was the most commonly prescribed 2-drug 
combination, whereas in a study by Jaganan et al., ACE inhibitors 
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with thiazide diuretics (34.3%) were the most commonly prescribed 
combination [22,27].
In the present study, the most commonly prescribed 3-drug combination 
was ARB+ thiazide+ CCB (25.6%) followed by an equal percentage of 
23.1% for ACE inhibitor+ CCB+ alpha agonist and ARB+ CCB+ alpha 
agonist. Similarly, Alavudeen et al. reported that ARB+ CCB+ diuretic 
(21.4%) was the most commonly used 3-drug combination [26]. Panda 
et al. had also shown ARB+ thiazide+ CCB (1.9%) as the most common 
3-drug combination prescribed, hence showing consistency [35]. 
According to Tamuno and Fadare and Kousalya et al., ACE inhibitor + 
diuretic + CCB (14.5% and 34.4%, respectively) was commonly used 
in the 3-drug combination group [27,28]. However, according to Etuk 
et al., inclusion of alpha methyldopa in the 3-drug combination therapy 
was found to be more common in the form of alpha methyldopa + ACE 
inhibitor + diuretic combination (17.2%) [29]. This was different from 
the present study wherein clonidine was the most frequently used alpha 
agonist used in combination with CCB and ARB or ACE inhibitor (23%).
We found that, among the monotherapy group, metoprolol showed 
maximum percentage reduction in SBP (16.8%) followed by a reduction 
of 16.6% seen in the enalapril group. This finding was supported by 
another study conducted by Beulah s et al. wherein beta blockers 
produced a greater percentage reduction of 31.1% followed by a 28.5% 
reduction seen in ACE inhibitors [34]. However, in a study conducted by 
Yasmeen et al., enalapril showed greater percentage reduction in SBP 
(18.8%) followed by 14.1% reduction in atenolol [20]. In relation to 
DBP, maximum percentage reduction was seen in the CCB group where 
the novel calcium antagonist cilnidipine produced 15.1% reduction 
followed by 12.8% reduction seen in amlodipine. This was supported 
by Etuk et al. where CCB monotherapy had shown to be effective in 
reduction of DBP (13.4%) [29]. However, in other studies where beta 
blockers and ACE inhibitors were predominantly used as monotherapy, 
beta blockers produced comparatively greater percentage decrease in 
DBP (15.1% and 18.3%, respectively) than ACE inhibitors (14.9% and 
15.9%, respectively) [20,34].
Among the 2-drug combination group, we observed greater percentage 
reduction in SBP (15.6%) with ACE inhibitor + CCB group. This finding 
was consistent with earlier studies wherein the ACE inhibitor + CCB 
group showed a greater percentage reduction (21.8%) in comparison 
to the other 2-drug combination groups [20,36-38]. In our study, we 
found a greater percentage decrease in DBP with ARB + CCB and beta 
blocker + CCB group (12.5%). According to Chrysant et al., ARB + CCB 
combination has shown to be effective [39]. A retrospective cohort 
study by Bisognano et al. showed that beta blocker + CCB group was 
more effective than beta blocker + ACE inhibitor and beta blocker + ARB 
combination as it had produced a 9.4% reduction in DBP [40]. However, 
in other studies such as Yasmeen et al. and Beulah et al., CCB + diuretic 
group had shown a greater reduction in DBP of 17.7% and 18.8%, 
respectively [20,34].
Table 9: Effect of 3-drug combination on systolic blood pressure (n=39)





Baseline (mean±SD) After (mean±SD)
ACE inhibitor+CCB+Alpha agonist 166.6±5.0 150.6±5.0 16.0±3.8 9.6 <0.001*
ARB+thiazide+CCB 162.0±7.8 135.0±9.7 27.0±4.8 16.7 <0.001*
ARB+CCB+Alpha agonist 164.0±6.6 136.0±5.3 28.0±7.2 17.1 <0.001*
Others 162.9±4.5 138.5±6.0 24.3±5.1 14.9 <0.001*
SD: Standard deviation, CCB: Calcium channel blocker, ARB: Angiotensin receptor blocker, SBP: Systolic blood pressure, mm Hg is Millimeter of mercury, SD is standard 
deviation for n=39 observations, *represents statistical significance, ACE: Angiotensin-converting enzyme
Table 10: Effect of 3-drug combination on diastolic blood pressure (n=39)





Baseline (mean±SD) After (mean±SD)
ACE inhibitor+CCB+Alpha agonist 95.5±5.2 84.4±5.2 11.1±3.3 11.6 <0.001*
ARB+thiazide+CCB 97.0±6.7 83.0±6.7 14.0±6.9 14.4 <0.001*
ARB+CCB+Alpha agonist 95.5±7.2 82.2±4.4 13.3±5.0 13.9 <0.001*
Others 90.9±5.3 80.9±5.3 10.0±6.3 11.1 <0.001*
SD: Standard deviation, CCB: Calcium channel blocker, ARB: Angiotensin receptor blocker, DBP: Diastolic blood pressure, mm Hg is Millimeter of mercury, SD is standard 
deviation for n=39 observations, *represents statistical significance, ACE: Angiotensin-converting enzyme
Table 11: Group-wise ADR analysis
Drug group Number of ADRs (n=30)
Monotherapy 20 (66.7)
2-drug combination 06 (20.0)
3-drug combination 04 (13.3)
ADR: Adverse drug reaction
Table 12: Drug-wise adverse drug reaction analysis
Drug name ADR n=30
Amlodipine Pedal edema 17 (56.7)
Enalapril Dry cough 05 (16.7)
Acute kidney injury 01 (3.3)
Telmisartan Dry cough 02 (6.7)
Hyponatremia 01 (3.3)
Hyperkalemia 01 (3.3)
Hydrochlorothiazide Hypokalemia 03 (10.0)
ADR: Adverse drug reaction
Table 13: Adverse drug reactions in monotherapy group
Drug ADR Number of ADRs (n=20)












                  (15%)
01
ADR: Adverse drug reaction
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In the present study, among the 3-drug combination group, ARB+ CCB+ 
alpha agonist had shown a greater percentage decrease in SBP (17.1%) 
whereas ARB+ thiazide+ CCB (14.4%) showed the best reduction in 
DBP. Maladkar et al. and Oparil et al. had shown the superiority of ARB+ 
thiazide+ CCB triple combination for control of DBP [41,42]. However, 
in the study by Yasmeen et al., beta blocker+ CCB+ ACE inhibitor 
produced maximum percentage decrease in SBP and DBP (16.6% and 
29.2%, respectively), whereas according to Beulah et al., ACE inhibitor + 
beta blocker + diuretic led to a greater percentage decrease in both SBP 
and DBP (39% and 18.3%) [20,34].
Upon comparison of efficacy between monotherapy and combination 
therapy of antihypertensives, it was seen that both were equally 
effective. Consistent with above findings, Yasmeen et al. had shown 
that all groups in monotherapy and combination therapy were equally 
effective in reducing BP [20]. Similarly, Beulah et al. also supported 
the present study with the same findings [34]. However, according to 
a meta-analysis conducted by Wald et al. on 11,000 patients from 42 
trials, combination of antihypertensive drugs from various classes is 
approximately 5 times more efficient than a 2-fold increase in the dose 
of one drug [43]. This could be due to synergistic action of individual 
antihypertensive drugs upon combination.
As shown in results, 15% of patients developed ADRs and most of 
the ADRs were seen in the monotherapy group (66.7%). However, 
according to Husain et al., combination therapy had shown drastically 
higher occurrence of ADRs of 61.8% as compared to monotherapy 
showing 38.2% of drug reactions [44]. This could probably be due to 
summation or additive effect of individual drugs in relation to their 
adverse effects when used as combination. Among the monotherapy 
group, amlodipine-induced pedal edema was the most common ADR 
noted (56.7%) followed by enalapril-induced dry cough (16.7%). This 
finding was supported by Beulah et al., where the most common adverse 
effect observed was amlodipine-induced pedal edema (22%) and the 
second most common adverse reaction was ACE inhibitor-induced 
dry cough (10%) [34]. The relatively lower incidence of pedal edema 
in the CCB-thiazide groups as compared to CCB monotherapy could be 
attributed to the diuretic action of thiazides. Moreover, the incidence 
of adverse effects was more commonly seen in the amlodipine group 
possibly because it was the most common drug prescribed in the 
present study. Other adverse effects noted were electrolyte imbalances 
such as hyponatremia, hypokalemia, and hyperkalemia. No serious 
ADRs were observed in our study.
According to modified Hartwig severity scale, all ADRs were mild to 
moderate in severity which was managed by either reduction in dosage 
or frequency or change in the suspected drug, reduced dosage, or 
change in the drug [45]. According to the WHO causality assessment 
system, all these ADRs were classified as ‘possible’ because all ADRs 
occurred in relation to the time of drug intake, but which could be 
justified by other coexisting diseases or drugs [16].
Non-pharmacological therapy which includes alterations in the 
standard of living can reduce and thereby aid in BP adjustment. 
These prove to be appreciable when applied in support to drug 
therapy. It can play a critical role in controlling BP by improving the 
effectiveness of antihypertensive drugs, reducing the risks associated 
with the cardiovascular system, and also decrease the amount of drugs 
required or their dosage. Weight reduction in overweight or obese 
individuals [46], implementation of DASH eating plan rich in potassium, 
calcium, and dietary sodium reduction, and regular exercises [47-49] 
are some of the variations in daily life that have shown improved 
outcomes in BP reduction.
The major limitation of this study was the shorter duration of the study 
period. All patients were followed up for only 8 weeks. A longer duration 
of the study would have been helpful in a better understanding of the 
efficacy and tolerability of the drugs as it would have been essential 
in the better assessment of the various long-term cardiovascular and 
mortality outcomes. Hence, patients have to be followed for a longer 
period to evaluate the efficacy and tolerability of the drugs.
CONCLUSION
Though monotherapy and combination therapy were equally effective 
with the latter producing fewer ADRs, combination therapy may be 
considered as a better treatment option in selected patient population. 
However, further studies of longer duration are required to determine 
the long-term benefits of various antihypertensive medications used 
as both monotherapy and combination therapy for this chronic and 
diverse health problem.
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